Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mingming Wei

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
International Urology and Nephrology|March 2, 2025
Observation of the efficacy and safety of obinutuzumab in the treatment of refractory idiopathic membranous nephropathyLuyao Li, Sha Wang, Mingming Wei, et al.
Journal of Medicinal Chemistry|February 3, 2025
Identification of a Potent and Selective CDK9 Degrader as a Targeted Therapeutic Option for the Treatment of Small-Cell Lung CancerYubo Wang, Mengmeng Wang, Lan Ma, et al.
Journal of Medicinal Chemistry|October 25, 2021
Proteolysis-Targeting Chimera (PROTAC) Modification of Dovitinib Enhances the Antiproliferative Effect against FLT3-ITD-Positive Acute Myeloid Leukemia CellsSheng Cao, Lan Ma, Yulin Liu, et al.
BMC Cancer|November 14, 2021
MicroRNA-1915-3p inhibits cell migration and invasion by targeting SET in non-small-cell lung cancerHongli Pan, Zhenhua Pan, Fengjie Guo, et al.
European Journal of Medicinal Chemistry|February 3, 2023
Discovery of novel and bioavailable histone deacetylases and cyclin-dependent kinases dual inhibitor to impair the stemness of leukemia cellsYulin Liu, Yujiao Wei, Xuan Wang, et al.
International Journal of Biological Macromolecules|December 26, 2024
Identification of chemical inhibitors targeting long noncoding RNA through gene signature-based high throughput screeningJun An, Huili Wang, Mingming Wei, et al.
Bioorganic Chemistry|April 11, 2021
In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC)Yubo Wang, Yuanyuan Zhou, Sheng Cao, et al.
Science Translational Medicine|September 24, 2025
USP5 inhibition enables potential therapy for t(8;21) AML through ubiquitin-mediated AML1-ETO degradation in patient-derived xenograftsLan Ma, Kun Zhang, Zixuan Zhang, et al.
Cancer Letters|May 26, 2024
Neratinib impairs function of m6A recognition on AML1-ETO pre-mRNA and induces differentiation of t (8;21) AML cells by targeting HNRNPA3Yulin Liu, Liting Zheng, Ying Li, et al.
European Journal of Medicinal Chemistry|April 16, 2024
Design, synthesis and evaluation of a pyrazolo[3,4-d]pyrimidine derivative as a novel and potent TGFβ1R1 inhibitorYubo Wang, Yulin Liu, Yan Zhang, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
International Urology and Nephrology|March 2, 2025
Observation of the efficacy and safety of obinutuzumab in the treatment of refractory idiopathic membranous nephropathyLuyao Li, Sha Wang, Mingming Wei, et al.
Journal of Medicinal Chemistry|February 3, 2025
Identification of a Potent and Selective CDK9 Degrader as a Targeted Therapeutic Option for the Treatment of Small-Cell Lung CancerYubo Wang, Mengmeng Wang, Lan Ma, et al.
Journal of Medicinal Chemistry|October 25, 2021
Proteolysis-Targeting Chimera (PROTAC) Modification of Dovitinib Enhances the Antiproliferative Effect against FLT3-ITD-Positive Acute Myeloid Leukemia CellsSheng Cao, Lan Ma, Yulin Liu, et al.
BMC Cancer|November 14, 2021
MicroRNA-1915-3p inhibits cell migration and invasion by targeting SET in non-small-cell lung cancerHongli Pan, Zhenhua Pan, Fengjie Guo, et al.
European Journal of Medicinal Chemistry|February 3, 2023
Discovery of novel and bioavailable histone deacetylases and cyclin-dependent kinases dual inhibitor to impair the stemness of leukemia cellsYulin Liu, Yujiao Wei, Xuan Wang, et al.
International Journal of Biological Macromolecules|December 26, 2024
Identification of chemical inhibitors targeting long noncoding RNA through gene signature-based high throughput screeningJun An, Huili Wang, Mingming Wei, et al.
Bioorganic Chemistry|April 11, 2021
In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC)Yubo Wang, Yuanyuan Zhou, Sheng Cao, et al.
Science Translational Medicine|September 24, 2025
USP5 inhibition enables potential therapy for t(8;21) AML through ubiquitin-mediated AML1-ETO degradation in patient-derived xenograftsLan Ma, Kun Zhang, Zixuan Zhang, et al.
Cancer Letters|May 26, 2024
Neratinib impairs function of m6A recognition on AML1-ETO pre-mRNA and induces differentiation of t (8;21) AML cells by targeting HNRNPA3Yulin Liu, Liting Zheng, Ying Li, et al.
European Journal of Medicinal Chemistry|April 16, 2024
Design, synthesis and evaluation of a pyrazolo[3,4-d]pyrimidine derivative as a novel and potent TGFβ1R1 inhibitorYubo Wang, Yulin Liu, Yan Zhang, et al.
Pageof 7